Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction

• Hiroshi Kawada

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Jun Fujita

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Kentaro Kinjo

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Yumi Matsuzaki

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Mitsuyo Tsuma

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Hiroko Miyatake

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Yukari Muguruma

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Kosuke Tsuboi

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Yuji Itabashi

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Yasuo Ikeda

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Satoshi Ogawa

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Hideyuki Okano

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Tomomitsu Hotta

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Kiyoshi Ando

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

• Keiichi Fukuda

  From the Division of Hematology, the Department of Medicine, Tokai University School of Medicine; Research Center for Regenerative Medicine, Tokai University School of Medicine; the Department of Internal Medicine, Keio University School of Medicine; the Institute for Advanced Cardiac Therapeutics, Keio University School of Medicine; Core Research for Evolutional Science and Technology-Japan Science and Technology and Department of Physiology, Keio University School of Medicine, Japan.

抄録

Bone marrow (BM) cells are reported to contribute to the process of regeneration following myocardial infarction. However, the responsible BM cells have not been fully identified. Here, we used 2 independent clonal studies to determine the origin of bone marrow (BM)–derived cardiomyocytes. First, we transplanted single CD34– c-kit+Sca-1+ lineage– side population (CD34–KSL-SP) cells or whole BM cells from mice ubiquitously expressing enhanced green fluorescent protein (EGFP) into lethally irradiated mice, induced myocardial infarction (MI), and treated the animals with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the damaged myocardium. At 8 weeks after MI, from 100 specimens we counted only 3 EGFP+ actinin+ cells in myocardium of CD34– KSL-SP cells in mice that received transplants, but more than 5000 EGFP+ actinin+ cells in whole BM cell in mice that received transplants, suggesting that most of EGFP+ actinin+ cells were derived from nonhematopoietic BM cells. Next, clonally purified nonhematopoietic mesenchymal stem cells (MSCs), cardiomyogenic (CMG) cells, that expressed EGFP in the cardiomyocyte-specific manner were transplanted directly into BM of lethally irradiated mice, MI was induced, and they were treated with G-CSF. EGFP+ actinin+ cells were observed in the ischemic myocardium, indicating that CMG cells had been mobilized and differentiated into cardiomyocytes. Together, these results suggest that the origin of the vast majority of BM-derived cardiomyocytes is MSCs.

収録刊行物

• Blood

  Blood 104 (12), 3581-3587, 2004-12-01

  American Society of Hematology

キーワード

• Cell Biology
• Hematology
• Immunology
• Biochemistry

詳細情報

• CRID: 1360292620572988928
• NII論文ID: 30022498459
• DOI: 10.1182/blood-2004-04-1488
• ISSN: 15280020
• ISSN: 00064971
• Web Site: http://ashpublications.org/blood/article-pdf/104/12/3581/1703722/zh802304003581.pdf
• データソース種別:
  • Crossref
  • CiNii Articles
  • KAKEN